BRPI0513932A - derivados de indol-2-carboxamidina como antagonistas de receptores de nmda - Google Patents
derivados de indol-2-carboxamidina como antagonistas de receptores de nmdaInfo
- Publication number
- BRPI0513932A BRPI0513932A BRPI0513932-5A BRPI0513932A BRPI0513932A BR PI0513932 A BRPI0513932 A BR PI0513932A BR PI0513932 A BRPI0513932 A BR PI0513932A BR PI0513932 A BRPI0513932 A BR PI0513932A
- Authority
- BR
- Brazil
- Prior art keywords
- atom
- carboxamidine derivatives
- formula
- nmda receptor
- indole
- Prior art date
Links
- NUNZGJKXTJMXGY-UHFFFAOYSA-N 1H-indole-2-carboximidamide Chemical class C1=CC=C2NC(C(=N)N)=CC2=C1 NUNZGJKXTJMXGY-UHFFFAOYSA-N 0.000 title abstract 6
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 abstract 1
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 1
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 abstract 1
- 108010038912 Retinoid X Receptors Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052736 halogen Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- -1 preferably dioxalane Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
Abstract
DERIVADOS DE INDOL-2-CARBOXAMIDINA COMO ANTAGONISTAS DE RECEPTORES DE NMDA A presente invenção se refere, portanto, primeiro a novos derivados de indol-2-carboxamidina da fórmula (I): em que o significado de: x é átomo de hidrogênio ou de halogênio, C~ 1~-C~ 4~ alquila, C~ 1~-C~ 4~ alcóxi, grupo trifluorometila; Y, V e Z independentemente são átomo de hidrogênio ou átomo de halogênio, hidróxi, ciano, C~ 1~-C~ 4~ alquilsulfonamido opcionalmente é substituído por um átomo halogênio ou átomos de halogênio, C~1 ~-C~ 4~ alcanoilamido opcionalmente substituído por um átomo de halogênio ou átomos de halogênio, trifluorometila, trifluorometóxi, C~ 1-~C~ 4~ alquila, grupo C~ 1~-C~ 4~ alcóxi ou grupos V e Z vizinhos, em dado caso junto com um ou mais hétero átomo idêntico ou diferente e -CH= e/ou grupos -CH~ 2~- podem formar um anel homo- ou heterocíclico com 4-7 elementos opcionalmente substituído, de preferência anel de dioxalano, benzeno, anel de dioxolano, A, B e C, independentemente, são átomo de carbono substituído ou um deles é átomo de nitrogênio e os seus sais. Outros objetivos da invenção são os processos para produção de derivados de indol-2-carboxamidina da fórmula (I) e a fabricação farmacêutica de medicamentos contendo esses compostos, bem como o processo de tratamentos com esses compostos o que significa administração, a um mamífero a ser tratado - incluindo um ser humano - de uma quantidade/quantidades eficazes de novos derivados de indol-2-carboxamidina da fórmula (I) da presente invenção como tal ou como um medicamento. Os novos derivados indol-2-carboxamidina da fórmula (1) da presente invenção são antagonistas altamente eficazes e seletivos do receptor de NMDA e, além disso, a maioria dos compostos são antagonistas seletivos do subtipo NR2B de receptor de NMDA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0401523A HUP0401523A3 (en) | 2004-07-29 | 2004-07-29 | Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them |
| PCT/HU2005/000078 WO2006010965A1 (en) | 2004-07-29 | 2005-07-21 | Indole-2 -carboxamidine derivatives as nmda receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0513932A true BRPI0513932A (pt) | 2008-05-20 |
Family
ID=89985408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0513932-5A BRPI0513932A (pt) | 2004-07-29 | 2005-07-21 | derivados de indol-2-carboxamidina como antagonistas de receptores de nmda |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20090048303A1 (pt) |
| EP (1) | EP1773770B1 (pt) |
| JP (1) | JP2008508248A (pt) |
| KR (1) | KR20070038502A (pt) |
| CN (1) | CN1989103A (pt) |
| AP (1) | AP2006003840A0 (pt) |
| AT (1) | ATE427299T1 (pt) |
| AU (1) | AU2005266160A1 (pt) |
| BR (1) | BRPI0513932A (pt) |
| CA (1) | CA2574155A1 (pt) |
| DE (1) | DE602005013675D1 (pt) |
| EA (1) | EA009981B1 (pt) |
| GE (1) | GEP20094606B (pt) |
| HU (1) | HUP0401523A3 (pt) |
| IL (1) | IL179485A0 (pt) |
| MA (1) | MA28815B1 (pt) |
| MX (1) | MX2007001052A (pt) |
| NO (1) | NO20071109L (pt) |
| TN (1) | TNSN07016A1 (pt) |
| WO (1) | WO2006010965A1 (pt) |
| ZA (1) | ZA200700325B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
| EP2536713A1 (en) | 2010-02-16 | 2012-12-26 | Pfizer Inc. | (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors |
| US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| US9562038B2 (en) * | 2010-11-18 | 2017-02-07 | Yale University | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| US9669030B2 (en) * | 2012-05-22 | 2017-06-06 | Autifony Therapeutics Limited | Hydantoin derivatives as Kv3 inhibitors |
| JO3579B1 (ar) | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| WO2019022179A1 (ja) * | 2017-07-28 | 2019-01-31 | 武田薬品工業株式会社 | 複素環化合物 |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9726388D0 (en) * | 1997-12-12 | 1998-02-11 | Cerebrus Ltd | Chemical compounds |
| US6319944B1 (en) * | 1999-05-10 | 2001-11-20 | Merck & Co., Inc. | Aryl amidines, compositions containing such compounds and methods of use |
| US6376530B1 (en) * | 1999-05-10 | 2002-04-23 | Merck & Co., Inc. | Cyclic amidines useful as NMDA NR2B antagonists |
| GB0015488D0 (en) * | 2000-06-23 | 2000-08-16 | Merck Sharp & Dohme | Therapeutic agents |
| HU227197B1 (en) * | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| JP2004253425A (ja) * | 2003-02-18 | 2004-09-09 | Tdk Corp | 積層コンデンサ |
-
2004
- 2004-07-29 HU HU0401523A patent/HUP0401523A3/hu unknown
-
2005
- 2005-07-21 CN CNA2005800247658A patent/CN1989103A/zh active Pending
- 2005-07-21 AP AP2006003840A patent/AP2006003840A0/xx unknown
- 2005-07-21 AU AU2005266160A patent/AU2005266160A1/en not_active Abandoned
- 2005-07-21 DE DE602005013675T patent/DE602005013675D1/de not_active Expired - Fee Related
- 2005-07-21 JP JP2007523161A patent/JP2008508248A/ja not_active Withdrawn
- 2005-07-21 BR BRPI0513932-5A patent/BRPI0513932A/pt not_active IP Right Cessation
- 2005-07-21 MX MX2007001052A patent/MX2007001052A/es active IP Right Grant
- 2005-07-21 WO PCT/HU2005/000078 patent/WO2006010965A1/en active Application Filing
- 2005-07-21 EA EA200700365A patent/EA009981B1/ru not_active IP Right Cessation
- 2005-07-21 CA CA002574155A patent/CA2574155A1/en not_active Abandoned
- 2005-07-21 GE GEAP20059893A patent/GEP20094606B/en unknown
- 2005-07-21 KR KR1020077000263A patent/KR20070038502A/ko not_active Application Discontinuation
- 2005-07-21 US US11/658,787 patent/US20090048303A1/en not_active Abandoned
- 2005-07-21 EP EP05764412A patent/EP1773770B1/en active Active
- 2005-07-21 AT AT05764412T patent/ATE427299T1/de not_active IP Right Cessation
-
2006
- 2006-11-22 IL IL179485A patent/IL179485A0/en unknown
-
2007
- 2007-01-11 ZA ZA200700325A patent/ZA200700325B/en unknown
- 2007-01-17 TN TNP2007000016A patent/TNSN07016A1/en unknown
- 2007-02-22 MA MA29702A patent/MA28815B1/fr unknown
- 2007-02-27 NO NO20071109A patent/NO20071109L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070038502A (ko) | 2007-04-10 |
| WO2006010965A1 (en) | 2006-02-02 |
| US20090048303A1 (en) | 2009-02-19 |
| IL179485A0 (en) | 2007-05-15 |
| HUP0401523A2 (en) | 2006-11-28 |
| CA2574155A1 (en) | 2006-02-02 |
| ZA200700325B (en) | 2008-05-28 |
| HU0401523D0 (en) | 2004-09-28 |
| EA200700365A1 (ru) | 2007-06-29 |
| HUP0401523A3 (en) | 2007-05-02 |
| JP2008508248A (ja) | 2008-03-21 |
| MA28815B1 (fr) | 2007-08-01 |
| EA009981B1 (ru) | 2008-04-28 |
| DE602005013675D1 (de) | 2009-05-14 |
| AP2006003840A0 (en) | 2006-12-31 |
| AU2005266160A1 (en) | 2006-02-02 |
| NO20071109L (no) | 2007-02-27 |
| TNSN07016A1 (en) | 2008-06-02 |
| EP1773770B1 (en) | 2009-04-01 |
| ATE427299T1 (de) | 2009-04-15 |
| MX2007001052A (es) | 2007-04-16 |
| CN1989103A (zh) | 2007-06-27 |
| EP1773770A1 (en) | 2007-04-18 |
| GEP20094606B (en) | 2009-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0513932A (pt) | derivados de indol-2-carboxamidina como antagonistas de receptores de nmda | |
| BRPI0718966B8 (pt) | composto, composição farmacêutica, inibidor plk1 e agente antitumoral | |
| EA200701176A1 (ru) | Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их | |
| BR112012014899A2 (pt) | composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus | |
| AR074876A1 (es) | Derivados de indol-pirimidina para tratar cancer | |
| TW200720266A (en) | Benzodioxane and benzodioxolan derivatives and uses thereof | |
| EA200970585A1 (ru) | Бензамидные производные как агонисты ер-рецепторов | |
| BR112014026383A2 (pt) | derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl1 | |
| BRPI0413152A (pt) | derivados de benzimidazol alquilado por n3 como inibidores de mek | |
| UY31069A1 (es) | Nuevos derivados de imidazoquinola, composiciones conteniendolos, proceso de preparacion y aplicaciones | |
| BRPI0515081A (pt) | derivados de fenilaminopirimidina como inibidores de bcr-abl cinase | |
| UY29246A1 (es) | Nuevos compuestos | |
| BRPI0908120A8 (pt) | Compostos que são inibidores de erk, composição faramacêutica e uso | |
| PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| UY30316A1 (es) | Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| BRPI0716069A2 (pt) | composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio | |
| BR112015008037A2 (pt) | compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção | |
| UA109525C2 (xx) | Алкіламідна сполука і її застосування | |
| BR122018070508B8 (pt) | derivados de arilamida triazol-substituída e seu uso | |
| BR112014001083A8 (pt) | composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto | |
| BRPI0900983B8 (pt) | composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso | |
| BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
| CO6270285A2 (es) | Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida | |
| BR112013017362A2 (pt) | composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |